-
Indian FMCG and pharma companies are accelerating acquisitions in nutraceuticals because the category offers a faster growth profile than their core businesses and gives them access to high-demand wellness segments such as protein, preventive health, and functional nutrition. Recent deals highlighted in the report include Marico’s stake in Cosmix, HUL’s move to take full ownership of OZiva, and USV Pharma’s acquisition of a majority stake in Wellbeing Nutrition.
What makes these targets attractive is not just category momentum, but operating leverage. Many of the acquired brands are digital-first, already have proven consumer traction, and fit neatly into larger companies’ distribution, branding, and portfolio strategies. HUL said OZiva has grown at a 130% CAGR since its earlier stake purchase, while Marico positioned Cosmix as a differentiated addition to its digital-first portfolio.
The bigger strategic shift is this: nutraceutical acquisitions are becoming a shortcut to enter preventive health without building from scratch. FMCG players can scale these brands through offline reach and last-mile distribution, while pharma companies can add scientific credibility, practitioner trust, and prescription-channel access.
Why it matters:
In India, wellness is no longer a niche adjacency. It is becoming a serious growth engine, and incumbents are using M&A to secure faster entry, stronger D2C capabilities, and more premium, health-led portfolios.
